NJ Leads the Way in Cell and Gene Therapy

On Nov 16, 2020

Disclaimer: Sponsored content articles do not reflect the opinions of New Jersey Business magazine or the New Jersey Business & Industry Association.

New Jersey’s vibrant innovation ecosystem has transformed the state into a growing hub for cell and gene therapy. By transplanting cells or manipulating genes in a patient’s body, these cutting-edge technologies are changing the trajectory of diseases once thought to be incurable and extending the longevity and quality of lives. The first such FDA approved therapy was brought to market from New Jersey by Novartis in 2017.

Top New Jersey companies are continuing to lead the way for next-generation therapeutics. Celularity developed CAR-T cell therapy for multiple myeloma and PTC Therapeutics pioneered treatment for Duchenne Muscular Dystrophy (DMD). Earlier this year, Hitachi Chemical announced a new cell and gene manufacturing facility in Allendale, NJ. The facility is the company’s first for cell and gene therapy commercialization and will more than doubles its existing manufacturing capacity in New Jersey.

The recent opening of BioCentriq was a major step forward in the evolving world of personalized medicine. This state-of-the-art cell and gene therapy contract development and manufacturing center is located on the New Jersey Institute of Technology (NJIT) campus in Newark, NJ. Industry giants and startups alike can augment in-house capacities or access facilities with an expert team to move from pre-clinical to human trials. To address the need for specialized workforce training, NJIT is also offering a professional science master’s degree program and professional graduate certificate in cell and gene therapy, among the first of its kind in the U.S.

New Jersey provides biotechnology companies many competitive advantages. We have more space at a more affordable price than Boston or California. Our robust transportation system, including the #1 regional airport system in the U.S., can expedite express deliveries to maintain the integrity of cell and gene therapies. Furthermore, innovators can access a high density of research universities and top healthcare systems to get their product to market.

Choose New Jersey is a privately funded 501 (c)(3) economic development organization with a mission to stimulate job creation and attract capital investment to New Jersey. Learn more at www.choosenj.com. 

Disclaimer: Sponsored content articles do not reflect the opinions of New Jersey Business magazine or the New Jersey Business & Industry Association.

Related Articles: